Pfizer, Inc. (NYSE:PFE) closed its last session at $36.12 with the change of +0.98%. The market capitalization of the company is $219.06B with an average Volume of 28.98 million shares. The stock currently has its 52-Week High range of $36.46 and 52-week low range of $28.25. The Price to Book (P/B) ratio stands at 3.44. The stock traded total quantity of 17.79 million shares.
For the current Fiscal Quarter, 15 analysts have given an average earnings per share forecast of $0.62. The Low Earnings per share estimate of the current Quarter is $0.57 and High Estimate is set at $0.69 according to these Analysts opinions. The Previous Year EPS of this Quarter is $0.56.
According to 12 analysts, an average sales Estimate of the current Fiscal quarter is $12.94B. The lower sales estimate is $12.49B and higher sales estimate is $13.32B according to these Analysts thoughts.
The Company currently has Highest Price Target of $54 and Lowest Price Target of $33. It has Median Price Targets of $38. Mean price target is set at $38.67 after consensus analysis of 21 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month 4 analysts have assigned this stock as Strong Buy where 10 assigned Buy, 9 analysts believe it’s a Hold, 0 said Underperform and 0 assigned Sell rating.
Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) ended its last trade at $7.25 with the move of +5.07%. The company has market value of $767.20M with the total traded volume of 1.53 million. The stock currently has its 52-Week top value of $10.51 and 52-week down value of $2.80. The price to book (P/B) ratio of the company is 14.78. Its previous closing price was recorded at $6.90.
For the current Fiscal Quarter, 10 analysts have given an Average earnings estimate of $-0.28 per share. According to the Analysts, the Low Estimate Earnings of the current Quarter is $-0.38 while High Estimate is $-0.15. The Previous Year EPS of this Quarter is $-0.26.
According to 9 analysts, an Average Revenue Estimate of the current Fiscal quarter is $8.51M. According to them, the Low Revenue estimate is $7.71M and High Revenue estimate is $9.07M.
The Company currently has High Price Target of $16. The Low and Mean Price Targets are $4 and $9 respectively. These price targets are set after consensus analysis of 9 brokers.
When having look at Recommendation Trends of the analysts polled at Thomson First call, for the Current month, 4 analysts have given this stock as Strong Buy where 3 issued Buy, 3 analysts think that it’s a Hold, 0 told Underperform and1 assigned Sell rating.